Obinutuzumab vs Tacrolimus in Membranous Nephropathy
Primary membranous nephropathy represents a leading cause of nephrotic syndrome in adults worldwide. Consequently, achieving long-term proteinuria remission remains crucial to prevent progressive kidney disease. Calcineurin inhibitors such as tacrolimus frequently induce initial responses. However, high relapse rates occur after drug withdrawal. The randomized phase 3 MAJESTY trial evaluated whether obinutuzumab provides superior long-term clinical outcomes.
Advancing Care in Primary Membranous Nephropathy
The MAJESTY trial enrolled 142 adult patients with biopsy-confirmed disease and persistent severe nephrotic-range proteinuria. Investigators randomly assigned participants to receive either intravenous obinutuzumab or oral tacrolimus. Specifically, the obinutuzumab group received infusions on day 1 and weeks 2, 24, and 26. In contrast, the tacrolimus group received oral therapy for 52 weeks followed by an eight-week taper. Therefore, researchers could directly evaluate whether B-cell depletion provided more durable remission than calcineurin inhibition. Importantly, the trial defined complete remission as a urinary protein-to-creatinine ratio of 0.3 or lower with stable kidney function.
Key Efficacy Outcomes and Remission Rates
At week 104, obinutuzumab produced remarkably superior efficacy outcomes across multiple clinical endpoints. In fact, 37% of patients in the obinutuzumab cohort achieved complete remission at two years. In comparison, only 5.7% of patients in the tacrolimus group maintained complete remission. Furthermore, the overall remission rate, encompassing both complete and partial responses, reached 51% with obinutuzumab versus 13% with tacrolimus. Thus, obinutuzumab delivered a statistically significant 38% advantage in overall remission. Moreover, obinutuzumab led to higher rates of complete remission as early as week 76.
Safety Profile and Clinical Implications
Both therapeutic regimens demonstrated acceptable but distinct adverse event profiles throughout the study period. Overall, treatment-related adverse events occurred in 48% of obinutuzumab recipients and 57% of tacrolimus recipients. Serious drug-related adverse events affected 10% of patients receiving obinutuzumab compared to 4.3% receiving tacrolimus. In addition, serious infections developed in roughly 5.6% of patients across each treatment arm. Approximately 38% of patients in the obinutuzumab cohort experienced infusion-related reactions. Consequently, clinician monitoring during intravenous administration remains essential. For clinicians managing high-risk nephrotic syndrome, these phase 3 findings clearly support targeted B-cell depletion to sustain remission.
Frequently Asked Questions
Q1: Why is obinutuzumab more effective than tacrolimus for long-term remission?
Obinutuzumab is a type II anti-CD20 monoclonal antibody that induces potent, deep B-cell depletion. In contrast, tacrolimus inhibits calcineurin pathways without eliminating the underlying autoimmune B-cell clones, which often leads to relapse after withdrawal.
Q2: What was the primary endpoint of the MAJESTY trial?
The primary endpoint was complete remission at 104 weeks. Specifically, investigators defined complete remission as a urinary protein-to-creatinine ratio of 0.3 g/g or lower with stable renal function.
Q3: What were the most common adverse events associated with obinutuzumab?
Infusion-related reactions occurred in approximately 38% of obinutuzumab recipients. Additionally, serious infections occurred in roughly 5.6% of patients, which mirrored the rate observed in the tacrolimus group.
References
- Airy M et al. In primary membranous nephropathy, obinutuzumab increased the likelihood of complete remission vs. tacrolimus at 104 wk. Ann Intern Med. 2026 Oct 06. doi: 10.7326/ANNALS-26-03622-JC. PMID: 42832810.
- Fervenza FC et al. Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy. N Engl J Med. 2026 Jun 05. doi: 10.1056/NEJMoa2602678. PMID: 42246654.
- Rovin BH et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
